carbamazepine epoxide

08/01/2013 - "Carbamazepine epoxide (i.c.) completely abolished allodynia when co-injected with strychnine (mean 83.2%; 95% CI 78.1 to 88.4) vs strychnine alone (mean 3.2%; 95% CI -0.9 to 7.2) (P < 0.0001). "
08/01/2013 - "The actions of conventional first-line treatment (carbamazepine epoxide [CBZe]) and clinically ineffective morphine were tested for trigeminal dynamic mechanical allodynia produced by intracisternal strychnine. "

04/01/2016 - "Our study aimed to determine the relationship between the administered daily dose of CBZ and its pharmacokinetic parameters, including concentrations of CBZ and carbamazepine-10,11-epoxide (CBZ-E) plasma levels, and the metabolic ratio of CBZ-E to CBZ, in Tunisian patients with epilepsy. "
08/01/2014 - "EPHX1 c.337T>C polymorphisms may contribute to the risk of severe CBZ-SJS/TEN by increasing the concentration of a CBZ metabolite, CBZ-10,11-epoxide, in patients with epilepsy."
08/01/1990 - "Carbamazepine-10,11-epoxide in epilepsy. "
12/01/1984 - "A method of measuring carbamazepine-10,11-epoxide (CBZ-10,11-EPOX) has been developed and used to monitor plasma concentrations in children suffering from various forms of epilepsy. "
12/01/1984 - "Correlation between plasma carbamazepine-10,11-epoxide concentration and drug side-effects in children with epilepsy."

08/01/1994 - "We report the first study of carbamazepine and carbamazepine-10,11-epoxide concentrations determined by using intracerebral microdialysis in three patients undergoing depth electrode studies for the evaluation of medically intractable epilepsy. "
01/01/1996 - "Using a newly developed microdialysis probe which allows continuous monitoring of drugs in blood, we have studied the pharmacokinetics of various antiepileptic drugs (carbamazepine, and its primary metabolite carbamazepine-epoxide, phenytoin primidone and phenobarbitone) in 5 patients (2 male, 3 female, aged 40-50 years) with intractable epilepsy. "

12/01/2019 - "In adults with focal seizures, adjunctive BRV treatment does not affect plasma concentrations of the evaluated AEDs but increases carbamazepine epoxide metabolite. "
06/01/1994 - "Our experience shows that inconspicuous elevation of carbamazepine-epoxide levels during polytherapy may precipitate a distinct state of drug toxicity characterized by severe exacerbation of seizures. "
01/15/1993 - "The levels of CBZ and CBZ-10,11-epoxide were substantially reduced over the course of treatment in all three strains, such that the levels of the two compounds in plasma and brain could not account for the decreased susceptibility to cocaine seizures observed following chronic CBZ. "
08/01/1990 - "The effects of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, were evaluated in seven outpatients with frequent epileptic seizures. "
04/01/1989 - "Carbamazepine and carbamazepine-epoxide serum concentrations in some resistant cases of complex partial seizures."

06/01/1994 - "Our experience shows that inconspicuous elevation of carbamazepine-epoxide levels during polytherapy may precipitate a distinct state of drug toxicity characterized by severe exacerbation of seizures. "
12/01/1984 - "Correlation between plasma carbamazepine-10,11-epoxide concentration and drug side-effects in children with epilepsy."
03/01/2003 - "Patch testing with carbamazepine and its main metabolite carbamazepine epoxide in cutaneous adverse drug reactions to carbamazepine."
01/01/2018 - "Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02."